2024
Post-Acute sequelae of COVID-19 in pediatric patients within the United States: A Scoping Review
Miller C, Borre C, Green A, Funaro M, Oliveira C, Iwasaki A. Post-Acute sequelae of COVID-19 in pediatric patients within the United States: A Scoping Review. American Journal Of Medicine Open 2024, 100078. DOI: 10.1016/j.ajmo.2024.100078.Peer-Reviewed Original ResearchClinical epidemiologyPost-acute sequelae of COVID-19High risk of biasLack of standardized definitionsPost-acute sequelaeRisk of biasSequelae of COVID-19United StatesScoping reviewComprehensive literature searchUS childrenShort follow-up durationFollow-up durationInclusion criteriaFemale sexOlder ageRisk factorsSARS-CoV-2 infectionLiterature searchChest painHigh riskOptimal preventionPediatric patientsPersistent symptomsCOVID-19
2021
Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel
Zell J, Wisnewski AV, Liu J, Klein J, Lucas C, Slade M, Iwasaki A, Redlich CA. Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel. PLOS ONE 2021, 16: e0251114. PMID: 34460832, PMCID: PMC8405017, DOI: 10.1371/journal.pone.0251114.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Live SARS-CoV-2Moderate SARS-CoV-2SARS-CoV-2 seroprevalenceWork-related risk factorsTransportation-related occupationsSerum IgG levelsAntigen-specific IgGIgG seropositivity rateBiomarkers of infectionSARS-CoV-2 spikeCOVID-19 exposureUS National Guard soldiersMilitary personnelIgG levelsSeropositivity rateHumoral responseSerum IgGViral exposureBlack raceRisk factorsOdds ratioStudy populationNational Guard soldiersDemographic dataClinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection
McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. PLOS ONE 2021, 16: e0243291. PMID: 33788846, PMCID: PMC8011821, DOI: 10.1371/journal.pone.0243291.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionYale New Haven HealthSARS-CoV-2Hospital mortalityRisk of admissionMale sexRisk factorsSARS-CoV-2 testingInvasive mechanical ventilationSevere acute respiratory syndrome virusBurden of diseaseRT-PCR testingAcademic health systemDiverse patient populationsRespiratory syndrome virusEthnic groupsAdult patientsClinical characteristicsDischarge dispositionRespiratory supportPrimary outcomeTreatment guidelinesMechanical ventilationRetrospective studyPatient populationSex differences in immune responses
Takahashi T, Iwasaki A. Sex differences in immune responses. Science 2021, 371: 347-348. PMID: 33479140, DOI: 10.1126/science.abe7199.Peer-Reviewed Original ResearchConceptsImmune responseCOVID-19Sex differencesSevere COVID-19Risk of deathHigher mortality riskCOVID-19 mortalityPossible biological mechanismsCOVID-19 incidenceMale sexRisk factorsSevere diseaseHigh riskMortality riskMale sex biasOld maleSex-disaggregated dataBehavioral factorsBiological sex differencesDeathVulnerable groupsRiskBiological mechanismsMalesSex
2020
Chapter 43 Mucosal Vaccines for Genital Herpes
Oh J, Iwasaki A. Chapter 43 Mucosal Vaccines for Genital Herpes. 2020, 723-734. DOI: 10.1016/b978-0-12-811924-2.00043-2.Peer-Reviewed Original ResearchGenital herpesMucosal vaccinesHSV-2Immune responseSensory neuronsHerpes simplex virus type 2Simplex virus type 2Genital mucosal epitheliaLocal immune responseDorsal root gangliaHSV type 1Host immune responseVirus type 2Painful ulcersGenital mucosaMucosal immunityAsymptomatic sheddingHIV transmissionRoot gangliaRisk factorsSystemic immunityClinical trialsLifelong infectionMucosal epitheliumAntiviral drugs
2017
β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares
Goldberg E, Asher J, Molony R, Shaw A, Zeiss C, Wang C, Morozova-Roche L, Herzog R, Iwasaki A, Dixit V. β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. The Journal Of Immunology 2017, 198: 206.18-206.18. DOI: 10.4049/jimmunol.198.supp.206.18.Peer-Reviewed Original ResearchKetogenic dietGouty flaresNLRP3 inflammasomeSmall clinical trialsCurrent treatment strategiesMajor risk factorNLRP3-dependent ILAnti-inflammatory moleculesIL-1R antagonistAlternate metabolic fuelsGout flaresJoint destructionGout patientsIL-1βIntense painRisk factorsClinical trialsInflammatory neutrophilsTreatment strategiesImmune responseUrate crystalsBacterial infectionsNeutrophilsGoutNLRP3β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
Goldberg EL, Asher JL, Molony RD, Shaw AC, Zeiss CJ, Wang C, Morozova-Roche LA, Herzog RI, Iwasaki A, Dixit VD. β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. Cell Reports 2017, 18: 2077-2087. PMID: 28249154, PMCID: PMC5527297, DOI: 10.1016/j.celrep.2017.02.004.Peer-Reviewed Original ResearchConceptsKetogenic dietGouty flaresΒ-hydroxybutyrateMajor risk factorAnti-inflammatory moleculesNLRP3-dependent mannerAlternate metabolic fuelsGout flaresJoint destructionIL-1βIntense painInterleukin-1βNLRP3 inflammasomeRisk factorsInflammatory neutrophilsBacterial infectionsNeutrophilsNLRP3Immune defenseGoutMetabolic fuelsBHBS100A9 fibrilsDietPain
2013
Generating protective immunity against genital herpes
Shin H, Iwasaki A. Generating protective immunity against genital herpes. Trends In Immunology 2013, 34: 487-494. PMID: 24012144, PMCID: PMC3819030, DOI: 10.1016/j.it.2013.08.001.Peer-Reviewed Original ResearchConceptsGenital herpesHerpes simplex virus infectionSimplex virus infectionSignificant risk factorsClinical vaccine trialsRecurrent symptomsHSV infectionProtective immunityViral sheddingVaccine trialsRisk factorsChronic diseasesVirus infectionHIV-1Clear infectionAntiviral drugsHost responseHerpesVaccine designInfectionMillions of peopleSpread of diseaseDiseaseRecent studiesVaccine